Biocon to market US cancer drug in South Asia, Gulf

By IANS

Bangalore : Biocon Ltd, India’s leading biotech firm, has entered into a licensing agreement with a US-based company to market a breast cancer drug in Pakistan, Bangladesh, Sri Lanka, the United Arab Emirates, Saudi Arabia and Kuwait, it was announced Friday.


Support TwoCircles

According to a company statement here Friday, Biocon will pay royalty to Abraxis BioScience Inc on net sales in South Asia and the Gulf region.

“Abraxane will add value to our onco-therapeutics marketing strategy and benefit patients both in South Asia and the Gulf region through in-house and licensed products,” Biocon chairperson Kiran Mazumdar-Shaw said in the statement.

The US pharma applied in July to the Indian health ministry for clearance to market the cancer drug in the country.

SUPPORT TWOCIRCLES HELP SUPPORT INDEPENDENT AND NON-PROFIT MEDIA. DONATE HERE